Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer

Part of paid clinical trials in Chicago, Illinois.

Sponsor
Vanderbilt-Ingram Cancer Center
Study ID
NCT00416650
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well erlotinib works in treating patients with advanced non-small cell lung cancer.

Key Dates

First listed
Dec 28, 2006
Start date
Jul 31, 2002
Status verified
Mar 2013
Primary completion
Oct 31, 2007
Completion
Mar 31, 2013

Study Design

Enrollment
16 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Therapeutic Intervention
    Patients will receive erlotinib (OSI-774) 150 mg daily by mouth. If specified toxicities occurs, the dose may be reduced.

Primary Outcome Measure

Major objective response rate (complete response and partial response) [ Time Frame: At 4 weeks and then every 8 weeks ]

Locations (4)

FacilityCityStateZIPSite coordinators
Northwestern Memorial HospitalChicagoIllinois60611-
Memorial Sloan-Kettering Cancer CenterNew YorkNew York10021-
Vanderbilt-Ingram Cancer CenterNashvilleTennessee37232-
MD Anderson Cancer CenterHoustonTexas77030-

Find similar trials in Chicago, IL

By condition
Lung cancer
By specialty
OncologyLung oncologyLung disease
By research site
Northwestern Memorial Hospital· Chicago, ILMemorial Sloan-Kettering Cancer Center· New York, NYVanderbilt-Ingram Cancer Center· Nashville, TNMD Anderson Cancer Center· Houston, TX

Related Studies